Full Press Release Details
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) --Monte Rosa Therapeutics, Inc.(Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences:
Webcasts of the fireside chats will be accessible via the “Events & Presentations” section of Monte Rosa’s website atir.monterosatx.com, and archived versions will be made available for 30 days following the presentations.
About Monte RosaMonte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. For more information, visitwww.monterosatx.com.